Very recent clinical advances using Abeta monoclonal antibodies that interact with both soluble Abeta oligomers and insoluble fibrillar ABeta, have demonstrated a reduction in Abeta burden correlating with a slowing of cognitive decline in early Alzheimer’s patients and have renewed confidence in the Abeta approach. Cognition Therapeutics has a first candidate in the clinic and has back-up candidates moving through its late preclinical pipeline.

By leveraging the expertise of its scientists at characterizing oligomeric proteins and their unique screening know-how in this area, Cognition Therapeutics has also initiated a discovery and development program for drug candidates to treat Parkinson’s dementia.